KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2016 - 2025)

Rigel Pharmaceuticals has reported Current Deferred Revenue over the past 15 years, most recently at $1.4 million for Q3 2025.

  • Quarterly results put Current Deferred Revenue at $1.4 million for Q3 2025, changed 0.0% from a year ago — trailing twelve months through Sep 2025 was $1.4 million (changed 0.0% YoY), and the annual figure for FY2024 was $1.4 million, changed 0.0%.
  • Current Deferred Revenue for Q3 2025 was $1.4 million at Rigel Pharmaceuticals, roughly flat from $1.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RIGL hit a ceiling of $9.5 million in Q1 2021 and a floor of $1.4 million in Q2 2023.
  • Median Current Deferred Revenue over the past 5 years was $1.4 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 362.74% in 2021 and later tumbled 77.93% in 2022.
  • Rigel Pharmaceuticals' Current Deferred Revenue stood at $2.6 million in 2021, then crashed by 47.27% to $1.4 million in 2022, then fell by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
  • The last three reported values for Current Deferred Revenue were $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025) per Business Quant data.